{"brief_title": "Efficacy and Safety Evaluation of Pegamotecan (PEG-camptothecin) in Advanced or Metastatic Soft Tissue Sarcoma", "brief_summary": "The purpose of this study is to evaluate the safety and efficacy of Pegamotecan (Peg-Camptothecin) in patients with Advanced or Metastatic Soft Tissue sarcoma.", "condition": ["Sarcoma, Soft Tissue"], "intervention_type": ["Drug"], "intervention_name": ["Pegamotecan"], "criteria": "Inclusion Criteria: - Histologically or cytologically confirmed diagnosis of soft tissue sarcoma with measurable disease. - Target tumors outside prior radiation field(s). - Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. - Adequate hematologic profile, as determined by hemoglobin, platelet, and neutrophil count. - Adequate renal function - Adequate liver function - No history of hemorrhagic cystitis or evidence of microscopic hematuria - Capable of understanding the protocol requirements and risks and providing written informed consent. - Either 0 or 1 prior chemotherapy regimens Exclusion Criteria: - Subject has a diagnosis of gastrointestinal stromal tumors. - Concurrent serious medical illness unrelated to tumor within the past 6 months. - Known chronic infectious disease, such as AIDS or hepatitis. - Positive screening pregnancy test or is breast-feeding. - A female or male subject of reproductive capacity unwilling to use methods appropriate to prevent pregnancy during the course of this study. - Receiving concurrent chemotherapy, radiotherapy, or surgery, or has received wide field radiation within the previous 4 weeks. - History of another active malignancy (except non-melanoma skin cancer and carcinoma in situ of the cervix), unless in complete remission and off all therapy for that disease for the last 2 years. - Known or clinically suspected brain metastases. - Received more than one prior treatment regimen (excluding adjuvant or neoadjuvant therapy) for soft tissue sarcoma. - Received any investigational drug within the last 30 days. - Not fully recovered from any prior surgery (at least 4 weeks recovery period for major surgery), and from any reversible side effects related to the administration of cytotoxic chemotherapy or radiation therapy. - Received a prior camptothecin analog (e.g., topotecan, irinotecan).", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "metastatic", "mesh_term": ["Sarcoma"], "id": "NCT00079950"}